Mountain Group Capital

Mountain Group News

Latest News

Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering

ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share.  In addition, Clearside has granted the underwriters a 30-day option to purchase up to an additional 1,080,000…

G1 Therapeutics Secures $47 Million Series C Financing

Proceeds will advance lead CDK4/6 inhibitors through early and mid-stage clinical trials, expand pipeline in multiple oncology indications

RESEARCH TRIANGLE PARK, N.C., May 11, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the completion of a $47 million Series C financing led by new investor Cormorant Asset Management. Additional new investors include Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital. All existing investors participated in the financing: Eshelman Ventures, Hatteras Venture Partners, Lumira Capital, MedImmune Ventures, Mountain Group…

Agriculture Start-Ups Get Boost From Big Firms and Investors

Compared with medicine, where small companies often lead in turning cutting-edge science into new drugs, agriculture has never had much start-up activity.

Mississippi Power, Silicon Ranch break ground on new solar energy facility

$100-million facility to generate enough electricity to power thousands of homes

Gulfport, Miss. – Mississippi Power and Silicon Ranch Corporation, along with local officials from the city of Hattiesburg, Forrest County and the Area Development Partnership, held a groundbreaking ceremony for the state’s largest solar farm today in Hattiesburg. When operational, the $100-million facility will generate 50 MW, enough electricity to supply power to approximately 6,500 homes. Members of the Mississippi Public Service Commission were also on hand for the ceremony,…

Partners Group invests USD 100 million in Silicon Ranch Corporation, a US developer, owner and operator of solar power production facilities

Partners Group, the global private markets investment manager, has agreed to provide USD 100 million in growth capital to Silicon Ranch Corporation (“Silicon Ranch”), a leading developer, owner and operator of solar energy facilities in the US, on behalf of its clients. The company’s existing investors will also participate in this corporate equity raise, which will support Silicon Ranch in building out its substantial portfolio of growth projects. With this…

Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion

Patients receiving a single treatment of ZUPRATA™ together with EYLEA® qualified for 60% fewer additional EYLEA retreatments over a 3-month period (p=0.013)

Patients in the ZUPRATA + EYLEA arm achieved 19 letters of improvement in Best Corrected Visual Acuity as compared to 11 letters of improvement following EYLEA-alone

Alpharetta, GA (April 26, 2016) – Clearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint.  In preliminary results from the trial, patients in the active arm (those receiving concomitant administration of ZUPRATA and EYLEA) qualified…

TVA and Silicon Ranch Partner on Large-Scale Solar Farm at NSA Mid-South

53 megawatt solar array will be the largest in Tennessee and will produce enough electricity to power more than 7,500 homes annually

MILLINGTON, Tenn. April 18, 2016 – Tennessee Valley Authority (TVA) has awarded Nashville-based renewable energy provider Silicon Ranch Corporation a long-term power-purchase agreement for a 53 megawatt solar project at Naval Support Activity (NSA) Mid-South in Millington, Tennessee. The solar array will be the largest in the state and will provide power to TVA customers at cost-competitive rates for the next twenty years. “TVA is committed to providing renewable energy…

A Local Startup Is Building the World’s Largest iPS Stem Cell Bank

Orig3n is crowdsourcing blood samples to build a massive repository for medical research.

Local biotech startup Orig3n is out for blood—literally. The company is trying to build the world’s largest bank of induced pluripotent (iPS) stem cells. To create this massive repository, called LifeCapsule, Orig3n is crowdsourcing blood samples at well-attended events like music festivals, health fairs, and last month’s Marine Corps Marathon in Washington, D.C. Founder Robin Smith told Forbes that this grassroots approach is an attempt to cut out the middlemen, i.e. slow-paced doctors and hospitals….

Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes

Nashville, Tenn. (January 26, 2016) – NuSirt Biopharma today announced results from a recently completed clinical trial in patients with type 2 diabetes using its patented technology combining leucine, an essential amino acid, and low doses of metformin. The data from this trial showed comparable improvement in several glucose measures coupled with greater improvement in liver enzymes when comparing a lower dose of metformin in combination with leucine versus full…

Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS™) Drug Administration

Alpharetta, GA (December 14, 2015) — Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced completion of enrollment in the company’s Phase 2 clinical trial (Tanzanite) for the treatment of macular edema associated with retinal vein occlusion (RVO). The trial uses CLS-TA, Clearside’s proprietary form of triamcinolone acetonide, injected by suprachoroidal space (SCS™) drug administration, concomitantly with…

← Previous Page&mdashNext Page →